Merck said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh ...

BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

With that as the backdrop, here's a rundown of three dividend stocks to buy with plans to only hold them for the next 10 ...

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Wolfe upgraded Merck to Outperform from Peer Perform and set a $135 price target, saying the drugmaker is approaching a new ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

AbbVie has made no secret of the fact that it’s taken an interest in the hotly contested PD-1xVEGF bispecific space. | AbbVie has made no secret of the fact that it's taken an interest in the hotly ...